# Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

> **NCT00428922** · PHASE2 · COMPLETED · sponsor: **Bhuvaneswari Ramaswamy** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00428922
- **Lead sponsor:** Bhuvaneswari Ramaswamy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-14
- **Primary completion:** 2012-11-01
- **Final completion:** 2017-02-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428922, "Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00428922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*